Chimeric autoantigen-T cell receptors (CATCRs)

Our group developed CATCR-T cells, an antigen-specific cellular therapy platform for the selective targeting of autoreactive B cells. CATCRs are CRISPR/Cas12-edited, re-engineered T cell receptors that use autoantigen domains to bind autoreactive B cell receptors, re-programming T cells to eliminate self-reactive B cells while preserving normal immune cells.

We are advancing CATCR-T cells for organ-specific and systemic autoimmune diseases, while working on off-the-shelf solutions that allow to advance precision immunotherapies at scale.